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ABSTRACT 
Background: The trunk plays a critical role in attenuating movement-related forces that 
threaten to challenge the body’s postural control system. For people with Parkinson’s disease 
(PD), disease progression often leads to dopamine-resistant axial symptoms, which impair 
trunk control and increase falls risk.  
 
Objective: This prospective study aimed to evaluate the relationship between impaired trunk 
muscle function, segmental coordination and future falls in people with PD.   
 
Methods: 79 PD patients and 82 age-matched controls completed clinical assessments and 
questionnaires to establish their medical history, symptom severity, balance confidence and 
falls history. Gait characteristics and trunk muscle activity were assessed using three-
dimensional motion analysis and surface electromyography. The incidence, cause and 
consequence of any falls experienced over the next 12 months were recorded and indicated that 
48 PD and 29 control participants fell at least once during this time.  
 
Results: PD fallers had greater peak and baseline lumbar multifidus (LMF) and thoracic erector 
spinae (TES) activations than control fallers and non-fallers. Analysis of covariance indicated 
that the higher LMF activity was attributable to the stooped posture adopted by PD fallers, but 
TES activity was independent of medication use, symptom severity and trunk orientation. 
Furthermore, greater LMF and TES baseline activity contributed to increasing lateral head, 
trunk and pelvis movements in PD fallers, but not non-fallers or controls.   
 
Conclusions: The results provide evidence of neuromuscular deficits for PD fallers that are 
independent of medications, symptom severity and posture and contribute to impaired head, 
trunk and pelvis control associated with falls in this population.  
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INTRODUCTION 
Parkinson’s disease (PD) is a heterogeneous neurodegenerative condition characterised by 
early symptoms of resting tremor1, slowness of movement2 and muscle rigidity2. However, with 
disease progression, patients may develop symptoms of postural instability2 and difficulties with 
initiating and maintaining rhythmic walking patterns (e.g. freezing of gait) that are often only 
partially responsive to pharmacological intervention3,4. Declines in physical functioning expose 
people with PD to a nine times greater risk of recurrent falls5,6 and prospective research shows 
up to 65% of people with PD will fall at least once in a 12-month period7-10. Unfortunately this 
increased risk of falling is compounded by the presence of impaired postural responses11,12, 
which significantly increase the risk of injury and future hospitalisation. Furthermore, the 
higher incidence of falls and fall-related injuries in individuals with Parkinson’s disease leads 
to an increased fear of falling, activity limitation and overall declines in independence and 
quality of life. 
 
Prospective research shows more than 50% of falls experienced by people with PD occur 
during walking or transferring tasks13; implicating postural instability and gait difficulties as 
likely contributors to a large percentage of the falls experienced by this population. By 
adulthood, human locomotion has become a relatively autonomous skill that relies upon the 
powerful and precisely-timed contractions of skeletal muscles to effectively coordinate the 
body’s segments. To better understand the effects of PD on neuromuscular function during 
gait, research has traditionally focused on the lower limb muscles, while the neuromuscular 
control of larger segments is commonly overlooked. From a mechanical perspective, the trunk 
represents almost 50% of the body’s mass14,15; hence effective control of this segment is 
essential to maintaining equilibrium during dynamic tasks. During both locomotor and non-
locomotor tasks, it is the role of the postural control system to coordinate the body’s segments 
  
 
to ensure that head movements are kept controlled, rhythmic and predictable (i.e. that the head 
remains stable)16,17. The head is one of the body’s most important natural frames of reference 
and, given the significance of vision and vestibular function to postural control and orientation, 
any unpredictable or excessive movement of this segment has the potential to increase one’s 
risk of balance loss and/or falls during dynamic tasks18-20. In bipedal gait, the structures of the 
trunk are believed to contribute to head stability by attenuating the forces associated with 
locomotion16,21. This task requires a fine balance between trunk stiffness and mobility22; a 
balance that is likely affected in people with PD who develop axial motor symptoms that 
increase segmental rigidity and postural abnormalities23. The reduced capacity for the trunk to 
attenuate movement-related forces may help to explain why PD fallers have an impaired 
capacity to stabilise their head during gait7 and a reduced ability to adapt to more challenging 
walking surfaces24.  
 
Despite the importance of trunk control in maintaining equilibrium during locomotion, there is 
a relative lack of research aimed at better understanding the relationship between deficits in 
trunk muscle function and the higher incidence of falls in people with PD. As such, this 
prospective study aimed to assess trunk muscle activation during walking in people with PD 
and age-matched controls to examine whether differences in trunk muscle function influence 
head, trunk and pelvis motion in these populations. Furthermore, to provide insight into the possible 
relationship between neuromuscular deficits, segmental motion and falls in these populations, these 
measures were also contrasted for participants who prospectively reported falling and those who did 
not.  Given research has shown that movements of the head and pelvis are larger7,24 and less 
rhythmic25 for people with PD who fall, it was hypothesised that patients with PD would have 
increased trunk muscle activity compared with controls and that these differences would be 
most prominent in patients who prospectively report falls. Additionally, it was hypothesised 
  
 
that increased muscle activity would correspond with increased segmental motion, due to the 
established relationship between axial rigidity and postural instability for people with PD23.  
 
METHODS 
Study Population 
Seventy-nine participants clinically-diagnosed with idiopathic PD based on the United 
Kingdom Brain Bank Criteria26 were recruited from neurology clinics and community support 
groups in South-East Queensland between August 2011 and June 2013 (Fig. 1).  During the 
same period, 82 healthy age- and gender-matched controls were randomly-recruited from the 
Brisbane metropolitan area via the Queensland state electoral roll. Prospective participants 
were sent an invitation via post, which outlined the aims, expected risk/benefits and time 
commitment associated with the study and were encouraged to contact the research team to 
discuss their eligibility if they were keen to be involved. Participants were excluded if they 
had; i) recently undergone surgery; ii) a recurrent history of musculoskeletal injury; iii) an 
inability to walk without assistance; iv) significant visual (Bailey-Lovie high contrast visual 
acuity >0.30 logMAR) or cognitive (Addenbrooke’s Cognitive Examination score <82 out of 
10027) impairment; or v) received deep brain stimulation.  In accordance with the Declaration 
of Helsinki, all participants provided written informed consent and the experimental protocol 
was approved by the Human Research Ethics Committee at the Australian Catholic University 
(Approval #Q2011 04).  Given the lack of literature concerning differences in muscle activation 
in people with PD who fall, a sample size estimate was derived using lower limb muscle 
activations presented previously for PD patients and age-matched controls28. On the basis of 
this calculation, it was determined that a minimum of 23 participants per group would be 
required to detect differences in muscle activation (Effect Size=0.82, Power=0.8, p=0.05). 
Given the falls rates reported for people with PD7,8 and community-dwelling older adults29,30, 
  
 
it was anticipated that for a sample comprising 80 participants per group, approximately 52 PD 
patients (66%) and 26 controls (33%) would report at least one fall during the 12-month follow-
up. As such, a target of 80 participants per group was deemed appropriate to not only achieve 
the required sample size per group, but also to accommodate an attrition rate of up to 15%. 
 
Insert Fig. 1 about here. 
 
Clinical Assessment 
Participants completed a series of questionnaires and clinical assessments with an experienced 
movement disorders researcher to establish their medical history, symptom severity and 
balance confidence. Specifically, symptom severity was assessed using the Unified Parkinson’s 
Disease Rating Scale (UPDRS)31, the Hoehn and Yahr stage score32 and the Schwab and 
England Activities of Daily Living scale33.  Additionally, freezing of gait and balance 
confidence were assessed using the Freezing of Gait questionnaire34 and the Activities-specific 
Balance Confidence scale35,36, respectively.  Postural instability and gait disability (PIGD) were 
assessed by summing the scores for items 13 to 15 and 27 to 30 from the UPDRS37, while PD 
sub-types38 and a global rigidity score39 were determined from the UPDRS using previously-
described methods. All assessments were completed within 1 to 2 hours of patients receiving 
their usual anti-parkinsonian treatment to ensure that they were optimally-medicated. Of the 
79 PD patients, 74 (93.7%) were being treated with levodopa or dopamine agonists. 
 
Gait Assessment 
The three-dimensional walking patterns and bilateral activity of the superficial trunk muscles 
were evaluated as participants completed four self-paced and barefoot walking trials along a 9-
metre long firm walkway. To facilitate the assessment of stride characteristics and segmental 
  
 
control, 34 reflective markers were positioned on the participants in accordance with the full-
body Vicon Plug-In Gait model (Vicon, Oxford, UK). Specifically, markers were attached to 
both legs (2nd metatarsal heads, lateral malleoli, calcanei, mid-shanks, lateral femoral 
epicondyles, mid-thighs), the pelvis (anterior-superior iliac spines, sacrum), the trunk (T10 and 
C7 spinous processes, xiphoid process, suprasternal notch, spine of right scapula), both arms 
(acromioclavicular joints, lateral humeral condyles, radial and ulnar styloids) and the head 
(bilaterally over the lateral brow and lambdoid sutures). The three-dimensional positions of 
these markers were tracked (150Hz) for two complete gait cycles (1 right; 1 left) within the 
central 6-metre section of the walkway by a previously calibrated eight-camera motion analysis 
system (Nexus 1.7; Vicon, Oxford, UK). 
 
Data were reconstructed to facilitate the calculation of spatiotemporal characteristics, including 
walking velocity, stride length, stride frequency (cadence) and step width.  Furthermore, the 
lateral and vertical displacements of the head, trunk and pelvis were calculated and normalised 
to walking velocity; providing insight into the control and stability of these segments. Given 
that the stooped (flexed) trunk posture adopted by PD patients40 has the potential to influence 
trunk extensor activity, differences in mean trunk flexion were assessed in the sagittal plane by 
calculating the angle formed between the longitudinal axes of the pelvis (defined by the 
anterior-superior iliac spines and sacrum markers) and trunk segments (defined by the T10, C7, 
xiphoid, suprasternal notch and scapula markers).  Finally, arm swing was calculated as the 
average linear displacement of both wrists in the sagittal plane7,24. Differences in 
spatiotemporal characteristics have been previously reported for people with Parkinson’s 
disease41-43 and differences in head control has been observed in Parkinson’s disease fallers 
while walking on firm7 and compliant surfaces24. 
 
  
 
Trunk Muscle Function 
Bilateral activation of the thoracic erector spinae (TES), lumbar multifidus (LMF) and external 
obliques (EO) were assessed using a 16-channel wireless surface EMG system (TeleMyo DTS, 
Noraxon U.S.A. Inc., Scottsdale, AZ, USA). Pairs of Blue Sensor M-00-S silver-silver chloride 
surface electrodes with a pre-gelled area of 154 mm2 and an overall diameter of 34 mm (Ambu 
Inc., Glen Burnie, MD, USA) were positioned bilaterally over the muscles of interest with a 
centre-to-centre distance of 34 mm.  Specifically, the TES was monitored by electrodes 
positioned 5 cm lateral to the 10th thoracic spinous process, while electrodes placed 2 cm lateral 
to the 3rd lumbar spinous process recorded LMF activity44.  Electrodes placed midway between 
the anterior superior iliac spine and the lowest point of the 10th rib recorded the bilateral activity 
of the EO muscles45.  Prior to positioning the electrodes, each site was prepared with an 
abrasive paste (Nuprep Skin Prep, Weaver and Company, Aurora, CO, USA) and cleaned 
thoroughly with isopropyl alcohol to reduce impedance.  For individuals with excessive hair, 
the skin was shaved prior to abrasion to improve adherence of the equipment to the skin. 
 
Myoelectric activity was sampled at 1500 Hz and at a resolution of 16-bit using wireless EMG 
transmitters with integrated pre-amplifiers (gain x 400, input impedance > 100 MΩ, common 
mode rejection ratio >100 dB, noise = <1 µV). To assist with combining the myoelectric and 
motion caption data, these systems were synchronised via a 16-bit analog-to-digital converter. 
 
Following data collection, the raw EMGs were detrended and cropped to include a complete 
gait cycle for each leg using the initial foot contact data derived from the motion analysis 
system.  Data were then processed using a wavelet-based adaptive filter46 to attenuate the 
influence of the ECG signal on trunk EMGs. Following full-wave rectification, data were low-
pass filtered using a 4th order dual-pass Butterworth filter (20 Hz cut-off) and processed using 
  
 
the root mean square (RMS) method with a 100 ms window length (150 samples) and an 
overlap of 149 samples. To minimise the likelihood of inadvertently filtering out important 
data, the cut-off frequency for the low-pass filter was informed by a residual analysis of the 
data and is commensurate with parameters used in previous research47.  
 
To facilitate group comparisons, EMGs were expressed as a percentage of the peak RMS 
amplitude of the EMGs collected during a series of three maximum voluntary isometric 
contraction (MVIC) performed for each of the muscles. As early research48,49 demonstrates that 
the rate of force development and relaxation is reduced in people with PD compared with age-
matched controls, there is a risk that a patient’s MVIC may be under-estimated, if appropriate 
measures are not taken during data collection. To ameliorate this risk, participants performed 
a minimum of two sub-maximal practice trials to confirm that; i) they understood the 
movement that they would be required to perform; and ii) to warm-up the muscles before the 
maximal efforts. Furthermore, as maximal force responses are more variable in people with 
PD49, each participant performed three maximal efforts separated by a minimum of 30-seconds 
rest. Finally, due to the slower rate of force production evident in people with PD48, raw EMGs were 
visually-inspected in real-time during data collection to ensure that activations plateaued and/or 
decreased prior to the participant relaxing. The peak RMS values recorded for each muscle 
during the MVIC trials were used to normalise the data and the peak normalised amplitudes 
for each muscle were averaged within each group to facilitate further analyses. Trunk muscles 
were examined as they have been shown to have regular activation patterns during 
unconstrained walking50 and contribute extensively to upper body orientation and segmental 
control during locomotion51. 
 
 
  
 
12-Month Prospective Follow-up 
Following the assessments, participants were asked to prospectively record any falls 
experienced over the next 12-month period on a series of falls diaries, which they completed 
daily and returned at the end of each month via reply-paid post. When participants recorded a 
fall, they were asked to report the timing, location and circumstances surrounding that fall.  A 
fall was defined as an unintentional coming to the ground or some lower level not as a result 
of a major intrinsic event or overwhelming hazard29. Using the prospective falls data, 
participants were divided into four groups that included people in the PD and control groups 
who reported no falls during the follow-up period (PD non-fallers; Control non-fallers) and 
those who reported one or more falls (PD fallers; Control fallers). 
 
Statistical Analysis 
A one-way analysis of variance (ANOVA) was used to assess differences in demographics, 
movement characteristics and muscle activity patterns between the PD patients and controls or 
the different faller sub-groups. When a significant main effect was identified for the faller sub-
groups, the Tukey’s Honestly Significant Difference post-hoc test was used to determine where 
the statistically significant differences existed.  The Tukey’s Honestly Significant Difference 
procedure controls for the overall significance level when performing all pairwise comparisons 
in the ANOVA and therefore reduces the likelihood of a Type 1 error. In circumstances where 
the assumptions of the ANOVA were violated, the non-parametric Kruskal-Wallis Test was 
used. The degree of association between the categorical variables was assessed with the chi-
square (χ2) test.  
 
The EMG outcomes were also analysed using an analysis of covariance (ANCOVA) to 
determine whether differences in medications (anti-depressants, benzodiazepines52), symptom 
  
 
severity (UPDRS total score, Hoehn and Yahr stage score) and/or trunk posture potentially 
influenced the amplitude of trunk EMGs. Furthermore, linear regression was used to determine 
whether differences in trunk muscle function were related to differences in head, trunk and 
pelvis control during walking. In addition to reporting the level of significance (p-values) for 
the selected outcomes, the minimal detectable change (MDC) was calculated using the formula 
1.96 x √2 x standard error of measurement and presented to provide insight into the clinical 
meaningfulness of the reported outcomes53.  Statistical procedures were conducted using SPSS 
22, with the level of significance set at p < 0.05. 
 
RESULTS 
Falls 
Forty-eight people with PD (61%) and 29 control participants (35%) reported at least one fall 
during the 12-month period, while 28 (35%) participants with PD and 13 (16%) controls 
reported falling twice or more. On the basis of the prospective falls data, participants were 
divided into four groups; PD Fallers (n = 48); PD Non-Fallers (n = 31); Control Fallers 
(n = 29); and Control Non-Fallers (n = 53). 
 
Demographics and Clinical Assessments 
The PD and control groups and the four faller sub-groups did not differ significantly for age, 
gender, height, mass or body mass index. However, PD participants had more previous falls 
and less balance confidence than controls, while PD fallers reported more previous falls and 
less balance confidence than PD non-fallers and the two control groups. PD non-fallers 
reported less balance confidence than the control fallers and non-fallers, while PD non-fallers 
and control fallers both recorded more previous falls than control non-fallers.  
 
  
 
The PD-specific clinical assessments indicated that PD fallers had more advanced symptoms, 
took larger daily doses of levodopa and had greater difficulties performing activities of daily 
living (UPDRS II) and simple motor tasks (UPDRS III). Despite this, sub-classification of 
patients in the two PD groups highlighted that each group comprised a similar proportion of 
patients with tremor-dominant, PIGD-dominant and mixed symptoms. With respect to the 
specific medications being used by the study cohort, the results indicated that a greater 
proportion of PD patients were taking anti-depressants and benzodiazepines than the control 
participants. Furthermore, a significantly greater percentage of PD fallers were taking anti-
depressants and benzodiazepines compared with the control non-faller group. With respect to 
the anti-parkinsonian medications being taken by the patient cohort, a similar proportion of PD 
fallers and non-fallers reported taking dopamine agonists, catechol-O-methyl transferase 
inhibitors and/or monoamine oxidase inhibitors (Table 1). There were no significant 
differences between the two patient sub-groups with respect to the proportion of each cohort 
that was taking one, two, three or four anti-parkinsonian medications at the time of their 
involvement in this study (χ2 = 3.49; p = 0.48). 
 
Insert Table 1 about here. 
 
Spatiotemporal Characteristics 
Participants with PD took shorter strides (p=0.001) and walked slower (p=0.009) than the age-
matched controls, but stride frequency (cadence) and step width did not differ between the two 
groups. Comparison of the four faller sub-groups indicated that the PD fallers, PD non-fallers 
and control fallers all took significantly shorter strides and walked slower than control non-
fallers. However, the MDC values reported for these outcomes indicated that only the 
differences observed between the PD fallers and control non-fallers and the PD non-fallers and 
  
 
control non-fallers were clinically meaningful. The four faller groups did not differ for cadence 
or step width (Table 2). 
 
Segmental Motion and Joint Kinematics 
Compared with controls, PD participants adopted a more stooped posture (greater trunk 
flexion) and had greater lateral head and trunk movement following adjustment for walking 
speed. Furthermore, the statistical analyses suggested that the patient group had less arm swing 
than the control group, but the MDC for this variable indicated that this difference was not 
clinically meaningful. The groups did not differ with respect to lateral pelvic movement or 
vertical head, trunk and pelvis displacement.  
 
PD fallers had more trunk flexion than control fallers (p=0.038) and non-fallers (p=0.001) and 
recorded more lateral head (p=0.009) and trunk (p=0.008) motion than control non-fallers. 
While control fallers also had greater lateral trunk motion than their non-falling counterparts 
(p=0.025), the MDC value suggested that this difference was not clinically important. 
Participants in the PD non-faller group did not differ significantly from the other faller sub-
groups for any of the measures of segmental motion or joint kinematics (Table 2). 
 
Trunk Muscle Activation 
The normalized trunk EMGs indicated that while the participants with PD demonstrated similar 
trunk muscle activation, they achieved significantly greater peak values for both the TES and 
LMF. Furthermore, the PD group had significantly greater TES and LMF activation between 
each of the dominant bursts of these muscles (i.e. greater baseline activity). Given that 
benzodiazepine and anti-depressant use was more common in PD fallers and that these patients 
had more advanced motor symptoms than their non-faller counterparts, the TES, LMF and EO 
  
 
data were further analyzed using an ANCOVA to determine whether these factors may have 
influenced the outcomes. The results of these analyses indicated that the reported activations 
of the anterior and posterior trunk muscles were not significantly influenced by benzodiazepine 
use, anti-depressant use, UPDRS total score or Hoehn and Yahr stage score. Furthermore, given 
PD patients walked with a more stooped posture than controls, the ANCOVA procedure was 
also used to account for any potential influence of trunk orientation on the TES and LMF data. 
Even following adjustment for differences in trunk posture, the PD group had significantly 
greater peak (F(1,158)=9.125, p=0.003) and baseline (F(1,158)=6.295, p=0.013) TES 
activation. In contrast, bilateral activation of the EO did not differ between the PD and control 
groups. 
 
Insert Fig. 2 about here. 
 
Fig. 2 provides representative bilateral TES activation patterns for the PD fallers, PD non-
fallers, control fallers and control non-fallers. The sub-group analyses indicated that the PD 
fallers typically demonstrated greater peak TES (Fig. 3) and LMF muscle activity than both 
control groups, although the difference between PD fallers and control non-fallers for peak 
LMF activity did not reach statistical significance (Table 2). Similarly, compared with both 
control groups, PD fallers had greater baseline activity between successive TES and LMF 
bursts, while PD non-fallers did not differ from the other groups for TES or LMF activation 
patterns.  The ANCOVA results indicated that the higher peak (F(3,156)=4.445, p=0.005) and 
baseline (F(3,156)=2.766, p=0.044) TES activities for the PD fallers were completely 
independent of the trunk flexion evident in these patients. The faller groups did not differ for 
peak or baseline levels of EO activity.  
 
Insert Table 2 and Fig. 3 about here. 
  
 
 
Trunk Muscle Activation and Segmental Motion 
Simple linear regressions evaluated the relationship between the trunk muscle activity (peaks 
and baseline) and the lateral displacement of the head, trunk and pelvis. For the PD fallers only, 
significant regression equations indicated that increased baseline TES activity was predictive 
of greater normalized lateral head (F(1,47)=13.985, p=0.001, B=4.180), trunk 
(F(1,47)=17.105, p<0.001, B=3.523) and pelvis (F(1,47)=15.564, p<0.001, B=2.011) 
movements. Similarly, significant regression equations showed that greater baseline LMF 
activity was predictive of larger normalized lateral head (F(1,47)=8.218, p=0.006, B=4.027), 
trunk (F(1,47)=9.213, p=0.004, B=3.307) and pelvis (F(1,47)=12.936, p=0.001, B=2.257) 
movements for PD fallers.  The regression equations returned for the other three sub-groups 
identified no significant association between trunk muscle activation and segmental motion. 
 
DISCUSSION 
This study investigated deficits in the activation of the anterior and posterior trunk muscles in 
people with PD who prospectively reported falling and their relationship to difficulties with 
coordinating and stabilising the head and trunk during locomotion. The results highlighted 
significant differences in trunk muscle function during walking for people with PD who 
prospectively fall. Commensurate with previous research7,24, PD fallers were also less able to 
control gait-related head and trunk movements when compared with the participants in the age-
matched control groups. Interestingly, the apparent difficulties that these patients had with 
regulating segmental control were directly influenced by their altered trunk muscle activation 
patterns, which suggested that such deficits in neuromuscular function may impair dynamic 
postural control in these individuals. 
 
  
 
In healthy adults, the activation patterns of the erector spinae and multifidus are characterised 
by two main bursts of activity during the gait cycle; each separated by a period of rest or 
relatively little activation50. Each of these bursts coincides with (or occurs shortly after) initial 
contact between the foot and the walking surface22,50,54. This bilateral activation of the erector 
spinae and multifidus muscles is believed to assist with keeping the trunk upright and over the 
pelvis by counteracting the trunk flexor moment that occurs during this phase54,55. The TES 
and LMF data collected in this study indicated that this basic pattern of activation was largely 
unaffected by the ageing process or the presence of PD. However, participants with PD and, in 
particular, those patients who prospectively reported falling typically had greater peak TES and 
LMF activations than both control groups. Furthermore, these participants also presented with 
higher levels of baseline activity for these muscles, which was suggestive of a greater level of 
coactivity during walking.  
 
Arguably, the higher levels of TES and LMF activity demonstrated by the PD fallers may be 
related to their more stooped walking posture and an increased reliance on these muscles to 
suspend the trunk’s mass against gravity. Interestingly, our results suggest that while the larger 
LMF peak and baseline activities recorded for the PD fallers were largely attributable to 
differences in trunk orientation, the observed TES activations were independent of trunk 
posture. Furthermore, differences in symptom severity and benzodiazepine or anti-depressant 
use were also shown to have little influence on TES muscle activation in this cohort. These 
findings are somewhat in contrast with previous research that has highlighted that the number 
of falls experienced by a person with PD in the previous month was significantly positively 
associated with anti-depressant use52. Nevertheless, our results seem to suggest that the higher 
TES activity observed in PD fallers was unlikely to represent a compensatory strategy to 
  
 
account for increased symptom severity or a neuromuscular adaptation in response to altered 
trunk posture, but rather represented a genuine abnormality in neuromuscular control. 
 
While the greater trunk muscle activity evident for the PD fallers could be viewed as a form of 
active stabilisation adopted by these patients, this interpretation incorrectly assumes that a 
stiffer trunk is representative of a more stable trunk. During activities of daily life, the human 
body is rarely truly static and, hence requires the head and trunk to move in an independent 
and coordinated manner to maintain equilibrium17,20. The linear regression analyses indicated 
that, for the PD faller group only, TES and LMF baseline activities were predictive of lateral 
head, trunk and pelvis movement during the walking task. Moreover, for every 1% increase in 
normalised baseline activity of the TES and LMF, lateral head movements were predicted to 
increase by approximately 4 cm, while predicted increases in lateral trunk and pelvic motion 
were 3.5 and 2 cm, respectively.  These findings suggested that the increased levels of baseline 
activity evident for the TES and LMF muscles served to increase the overall stiffness (rigidity) 
of the kinetic chain, resulting in the pelvis, trunk and head tending to move more as a single 
rigid unit rather than a collection of independent and well-coordinated segments.  Previous 
research provides support for this notion, showing that increased axial stiffness causes people 
with PD to rotate the thorax and pelvis in unison (i.e. in-phase)56,57, which significantly reduces 
their stability and increases their risk of overbalancing58.  Furthermore, given differences in 
trunk muscle activation patterns and lateral head and trunk movements were most prominent 
in those PD patients who prospective reported falling, our findings seem to strengthen the 
argument that such characteristics may be linked to the higher rate of falls experienced by this 
population7,24. Nevertheless, it should be noted that although control fallers had significantly 
greater lateral trunk motion than control non-fallers, neither peak nor baseline TES or LMF 
activation were significant related to this observation. These results seem to suggest that the 
  
 
mechanism(s) of falling in otherwise healthy older adults may be quite different to those 
experienced by people with PD. This notion may be supported by epidemiological research, 
which demonstrates that 69% of the falls from standing that are reported by PD patients are 
attributed to a loss of balance59, while only 9% of the falls experienced by community-dwelling 
older adults are attributed to this cause60. Given the apparent uniqueness of the physiological 
deficits exhibited by people with PD, it seems reasonable to suggest that falls prevention 
strategies be developed to specifically assist these individuals, rather than simply adopting 
programs developed for other populations.  
 
The identified relationship between increased axial rigidity and falls is well established23,61. 
Indeed, for over two decades, clinicians and scientists have reported the existence of at least 
two major subtypes of PD that are discernible based on their dominant motor symptom(s)38,62-
64. Despite the availability of several protocols for determining a patient’s disease sub-type, all 
tend to identify a group of patients whose primary motor symptom is resting tremor (tremor-
dominant type), a group whose primary symptoms are bradykinesia and rigidity (akinetic-rigid 
or PIGD type) and a group who presents with a combination of these two (mixed or 
indeterminate type). Given these classifications, one may intuitively assume that patients who 
present primarily with symptoms of bradykinesia and rigidity (akinetic-rigid type) or postural 
instability and gait disability (PIGD type) would be more likely to present with impaired axial 
muscle function. However, given there was a similar proportion of tremor-dominant and PIGD-
dominant patients in the PD faller and PD non-fallers groups, it seems that impaired trunk 
muscle function is not unique to patients who present with bradykinetic and/or rigid symptoms. 
Furthermore, linear regression revealed no significant relationship between the global rigidity 
score derived from the UPDRS and normalised ML head (p=0.701), trunk (p=0.697) or pelvis 
(p=0.726) movement in the PD population. These findings suggest that the assessment of trunk 
  
 
muscle function during gait may offer far greater benefits to existing clinic tests with respect to 
identifying patients who experience stability issues during dynamic tasks. As such, there appears to 
be a need to improve existing clinical assessments to ensure that ‘at risk’ patients can be 
effectively identified within the constraints of a standard clinical consultation. 
 
The relatively low rate of acceptance to participate in this study (25% for PD patients) may 
raise questions about the potential transferability of our findings to the wider PD community. 
With the information available for the non-responders, it was not possible to compare the 
disease characteristics, medication types and/or symptom severity of those included in the 
study with those who declined or did not respond. However, statistical comparison of the 
groups for age (p=0.765), gender distribution (p=0.586) and proximity to the testing location 
(p=0.512) showed no significant differences between those who were included and those who 
were not. While these results suggesting that the sample was somewhat representative of the 
wider PD community in this geographical region, the applicability of the reported outcomes to 
other PD populations should be considered. Furthermore, while our results provide evidence 
of impaired neuromuscular control of the superficial paraspinal muscles in PD fallers, it should 
be noted that it very difficult to accurately assess the activation of the deeper trunk muscles 
(e.g. thoracic multifidus), which are typically considered the primary stabilisers of the spine22. 
As such, it is plausible to suggest that the higher TES activity demonstrated by the PD fallers 
was representative of muscle substitution, rather than a specific deficit in this muscle’s 
function. The potential limitations associated with surface electromyography should therefore 
be considered when reviewing our findings. Finally, while the incidence of falls was 
established prospectively using daily falls diaries, participants were not required to return these 
until the end of each month. As such, it may be reasonable to argue that some participants may 
have completed multiple daily entries on a single day (i.e. retrospectively), which would have 
  
 
inadvertently increased the risk of recall bias. Nevertheless, it should be noted that the methods 
used were commensurate with previous research reporting the incidence of prospective falls65-
69, hence the potential risk of bias would not be expected to be any greater than observed in 
these earlier studies. 
 
Collectively, the results of this study assist with better understanding the mechanisms of 
postural instability in people with PD and suggest that those patients who fall demonstrate 
greater trunk muscle activity that is independent of medication use, symptom severity and trunk 
flexion and contributes to the impaired head and trunk control evident in this sub-population. 
Given that head and trunk control are critical to maintaining dynamic stability during 
locomotion, it is essential that the underlying mechanism(s) of axial PD symptoms are 
identified. Furthermore, as current pharmacological and surgical interventions are not always 
effective for managing these dopamine-resistant axial symptoms of PD23, future research 
should seek to identify alternate approaches to assist with the improvement of these symptoms. 
Exercise-based interventions seeking to improve the coordination, endurance and mobility of 
the trunk70 may prove beneficial for people with PD, as systematic evidence indicates that 
exercise is effective for improving some motor symptoms and patient scores on a number of 
balance and mobility scales71-75. 
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FIGURE LEGENDS 
Fig. 1: Flow diagram summarizing the recruitment, patient screening, data collection and 
follow-up procedures. 
 
Fig. 2: Representative bilateral thoracic erector spinae muscle activity for one participant from 
the; A) Parkinson’s disease Faller; B) Parkinson’s disease Non-Faller; C) Control Faller; and 
D) Control Non-Faller groups. Data represent full-wave rectified EMG data expressed as a 
percentage of the MVIC. The four vertical lines indicate the relative timing of the four 
consecutive foot contacts comprising the two gait cycles. 
 
Fig. 3: Mean (±1 SEM) bilateral thoracic erector spinae muscle activity for the; A) Parkinson’s 
disease Fallers; B) Parkinson’s disease Non-Fallers; C) Control Fallers; and D) Control Non-
Fallers. Data represent the ensemble averages for the root mean square EMG data, expressed 
as a percentage of the MVIC. The four vertical lines denote the relative timing of the four heel 
contacts that comprise the two consecutive gait cycles.  
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 Table 1: Demographic data and disease-specific scores for the participants with Parkinson’s disease, the age-matched controls participants and the faller and 
non-faller sub-groups. Data represent the mean (and standard error of the mean (SEM)) values or absolute numbers and percentages. Test 1 = one-way 
ANOVA; Test 2 = Kruskal-Wallis Test; Test 3 = χ2 test. 
  Parkinson’s Disease    Controls     
 All Faller Non-Faller  All Faller Non-Faller    
 (n = 79) (n = 48) (n = 31)  (n = 82) (n = 29) (n = 53)    
 Mean (SEM) Mean (SEM) Mean (SEM)  Mean (SEM) Mean (SEM) Mean (SEM)  Test Sig. 
Demographics           
Age (years) 68.1 (0.9) 69.1 (1.2) 66.5 (1.4)  69.6 (0.8) 69.5 (1.5) 69.6 (1.0)  1 ns 
Gender (male) 51 (64.6%) 29 (60.4%) 22 (71.0%)  50 (61.0%) 19 (65.5%) 31 (58.5%)  3 ns 
Height (cm) 168.2 (1.0) 166.8 (1.3) 170.6 (1.4)  168.9 (1.0) 168.8 (1.4) 168.9 (1.4)  2 ns 
Mass (kg) 74.3 (1.8) 71.9 (2.4) 77.9 (2.5)  78.5 (1.6) 79.8 (2.4) 77.8 (2.1)  1 ns 
BMI (kg/m2) 26.1 (0.5) 25.8 (0.8) 26.7 (0.7)  27.4 (0.4) 27.9 (0.7) 27.2 (0.6)  1 ns 
           
Falls History and Fear of Falls           
Activities-Specific Balance Confidence 77.5 (1.9) 72.7 (2.7) 85.0 (2.0)  94.1 (0.8) 92.3 (1.8) 95.1 (0.7)  2 a, b, c, d, e, f 
Previous Falls (12 months) 3.3 (1.4) 5.3 (2.3) 0.2 (0.1)  0.3 (0.1) 0.6 (0.1) 0.2 (0.1)  2 a, b, c, d, e, g 
           
Cognitive Function           
Addenbrooke’s Cognitive Examination 94.3 (0.6) 94.0 (0.7) 94.7 (0.9)  95.6 (0.5) 95.2 (1.0) 95.8 (0.5)  2 ns 
           
Medications           
Anti-Depressants 29 (36.7%) 21 (43.8%) 8 (25.8%)  13 (15.9%) 7 (24.1%) 6 (11.3%)  3 a, d 
Benzodiazepine 8 (10.1%) 7 (14.6%) 1 (3.2%)  2 (2.4%) 2 (6.9%) 0 (0.0%)  3 a, d 
Levodopa (mg/day) 655.7 (47.5) 763.0 (63.4) 489.7 (60.7)      1 b 
Dopamine Agonists 30 (38.0%) 16 (33.3%) 14 (45.2%)      3 ns 
Catechol-O-Methyl Transferase Inhibitors 28 (35.4%) 19 (39.6%) 9 (29.0%)      3 ns 
Monoamine Oxidase Inhibitors 12 (15.2%) 8 (16.7%) 4 (12.9%)      3 ns 
No PD Medication 5 (6.3%) 2 (4.2%) 3 (9.7%)      3 ns 
           
Neurological Exam           
Disease Duration (years) 6.1 (0.5) 7.2 (0.8) 4.2 (0.6)      2 b 
UPDRS I 3.2 (0.2) 3.4 (0.3) 2.8 (0.3)      1 ns 
UPDRS II 11.3 (0.6) 12.5 (0.8) 9.4 (0.7)      1 b 
UPDRS III 20.2 (1.0) 22.2 (1.4) 17.2 (1.3)      1 b 
UPDRS IV 4.0 (0.3) 4.4 (0.5) 3.2 (0.2)      2 ns 
UPDRS Total 34.7 (1.5) 38.2 (2.1) 29.4 (1.8)      1 b 
Tremor-dominant sub-type 17 (21.5%) 10 (20.8%) 7 (22.6%)      3 ns 
PIGD sub-type 51 (64.6%) 31 (64.6%) 20 (64.5%)      3 ns 
Indeterminate sub-type 11 (13.9%) 7 (14.6%) 4 (12.9%)      3 ns 
PIGD Score 4.7 (0.4) 5.7 (0.5) 3.1 (0.3)      2 b 
Global Rigidity Score 2.7 (0.3) 2.8 (0.4) 2.5 (0.4)      2 ns 
Freezing of Gait 5.8 (0.6) 7.2 (0.8) 3.6 (0.6)      2 b 
Hoehn & Yahr Stage Score 1.9 (0.1) 2.1 (0.1) 1.4 (0.1)      2 b 
Schwab & England ADL Scale 80.9 (1.1) 77.6 (1.4) 86.0 (1.2)      2 b 
ns: No difference between groups; a: PD different to Controls; b: PD Fallers different to PD Non-Fallers; c: PD Fallers different to Control Fallers; d: PD Fallers different to Control Non- 
Fallers; e: PD Non-Fallers different to Control Fallers; f: PD Non-Fallers different to Control Non-Fallers; g: Control Fallers different to Control Non-Fallers 
Table 2: Mean (and standard error of the mean (SEM)) segmental movement patterns, sagittal trunk kinematics and trunk muscle activation for the people 
with Parkinson’s disease, age-matched controls and the faller and non-faller sub-groups. The minimum detectable change (MDC) represents the smallest 
detectable change in each measure that can be considered a true change with 95% confidence. Test 1 = one-way ANOVA; Test 2 = Kruskal-Wallis Test. 
 Parkinson’s  Disease  Controls     
 All Fallers Non-Faller  All Faller Non-Faller     
 (n = 79) (n = 48) (n = 31)  (n = 82) (n = 29) (n = 53)     
 Mean (SEM) Mean (SEM) Mean (SEM)  Mean (SEM) Mean (SEM) Mean (SEM) MDC  Test Sig. 
Spatiotemporal Characteristics            
Walking Velocity (m/s) 1.14 (0.03) 1.11 (0.04) 1.18 (0.03)  1.25 (0.02) 1.19 (0.04) 1.27 (0.02) 0.09  2 a, d, f, g 
Stride Length (m) 1.19 (0.02) 1.16 (0.04) 1.24 (0.03)  1.31 (0.02) 1.26 (0.03) 1.33 (0.02) 0.08  2 a, d, f, g 
Cadence (steps/s) 1.90 (0.02) 1.89 (0.03) 1.91 (0.02)  1.90 (0.02) 1.88 (0.03) 1.92 (0.02) 0.07  1 ns 
Step Width (cm) 8.75 (0.38) 8.41 (0.53) 9.28 (0.52)  8.44 (0.38) 8.44 (0.54) 8.44 (0.51) 1.46  1 ns 
            
Segmental Motion (centimetres)            
Arm Swing 32.32 (1.93) 32.81 (2.39) 31.56 (3.27)  39.23 (1.82) 39.74 (4.13) 38.95 (1.72) 7.98  1 a 
Normalised Head Motion – Vertical 3.48 (0.10) 3.60 (0.15) 3.28 (0.09)  3.44 (0.06) 3.47 (0.11) 3.43 (0.07) 0.29  1 ns 
Normalised Head Motion – Lateral 8.08 (0.62) 8.87 (0.97) 
 
6.86 (0.41)  6.42 (0.25) 7.11 (0.50) 6.04 (0.25) 1.48  2 a, d 
Normalised Trunk Motion – Vertical 3.35 (0.07) 3.39 (0.10) 3.27 (0.09)  3.42 (0.05) 3.40 (0.10) 3.43 (0.06) 0.24  1 ns 
Normalised Trunk Motion – Lateral 7.22 (0.49) 7.84 (0.76) 6.27 (0.40)  5.81 (0.22) 6.43 (0.42) 5.47 (0.24) 1.26  2 a, d, g 
Normalised Pelvis Motion – Vertical 3.37 (0.07) 3.43 (0.10) 3.27 (0.08)  3.44 (0.05) 3.45 (0.10) 3.43 (0.06) 0.24  1 ns 
Normalised Pelvis Motion – Lateral 6.52 (0.32) 6.93 (0.46) 5.89 (0.38)  5.60 (0.20) 6.09 (0.34) 5.34 (0.24) 0.98  2 ns 
            
Joint Kinematics (degrees)            
ns: No difference between groups; a: PD different to Controls; b: PD Fallers different to PD Non-Fallers; c: PD Fallers different to Control Fallers; d: PD Fallers different to Control Non- 
Fallers; e: PD Non-Fallers different to Control Fallers; f: PD Non-Fallers different to Control Non-Fallers; g: Control Fallers different to Control Non-Fallers 
Trunk Flexion Angle 5.70 (0.94) 6.52 (1.30) 4.43 (1.30)  1.57 (0.57) 2.12 (0.98) 1.27 (0.71) 2.97  1 a, c, d 
            
Trunk Muscle Activity (% MVIC)            
Thoracic Erector Spinae – Peaks 31.48 (1.68) 33.61 (2.32) 28.24 (2.25)  23.58 (1.28) 21.52 (2.27) 24.71 (1.53) 5.80  1 a, c, d 
Thoracic Erector Spinae – Troughs 10.07 (0.86) 10.90 (1.16) 8.80 (1.26)  6.62 (0.42) 6.40 (0.72) 6.74 (0.52) 2.54  2 a, c, d 
Lumbar Multifidus – Peaks 39.49 (1.51) 41.39 (1.84) 36.50 (2.53)  34.09 (1.41) 29.91 (2.25) 36.37 (1.74) 5.79  1 a, c 
Lumbar Multifidus – Troughs 9.18 (0.72) 9.91 (0.97) 8.04 (1.04)  6.51 (0.55) 7.11 (1.17) 6.18 (0.57) 2.60  2 a, c, d 
External Oblique – Peaks 26.01 (1.50) 27.84 (2.07) 23.40 (2.07)  22.95 (1.30) 20.91 (2.03) 24.04 (1.66) 5.43  1 ns 
External Oblique – Troughs 11.61 (0.69) 12.29 (0.97) 10.66 (0.92)  10.78 (0.64) 10.07 (0.99) 11.17 (0.83) 2.57  1 ns 
